Insulet Corporation (PODD) fair value analysis
S&P 500 & Nasdaq · Updated 2026-10-19
PODD price how computed
Forward Fair Value verdict
UndervaluedPODD is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $135.28
- Sector
- Healthcare
- 12-month range
- $130.47–$346.36
- Market cap
- $9.38B
- From 52-week high
- -60.9%
- Shares outstanding
- 69.4M
- Rank in Healthcare by discount to fair value
- #96 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Insulet Corporation manufactures and markets the Omnipod insulin delivery system, a tubeless, wearable insulin pump designed for people with diabetes. The company operates globally, with a significant presence in the United States and Europe, serving patients who require insulin therapy management.
PODD currently ranks #96 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $9.38B
- P/E (trailing)
- 23x
- Revenue (TTM)
- $3.05B
- Net margin
- 12.3%
- EPS (TTM)
- $5.87
- Gross margin
- 70.2%
- Debt / equity
- 0.67
- Revenue growth (3-yr avg)
- 28.4%
- Shares outstanding
- 69.4M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Stable
- 52-week position
- The bottom quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 53 · neutral
- 50-day average
- $140.43
- 200-day average
- $185.76
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-04 (pre-market)
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+15.3%)
2026-03 ▲ beat (+19.3%)
2025-12 ▲ beat (+4.7%)
2025-09 ▲ beat (+7.8%)
2025-06 ▲ beat (+25.8%)
2025-03 ▲ beat (+29.1%)
2024-12 ▲ beat (+12.6%)
2024-09 ▲ beat (+18.4%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 15 buy · 10 hold · 0 sell (25 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $167
- Target vs last price
- +23.4%
What our data shows for PODD
- Our model validated 11 trailing price-to-earnings windows for PODD, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $130.47–$346.36.
- The 14-day relative strength index sits at a neutral 53.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for PODD
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent PODD news
TickrTrends' derived news-sentiment signal for PODD is currently leaning positive, computed from recent coverage.
- Insulet Corporation at Bernstein Insights Healthcare Leaders and Disruptors Transcript (gurufocus.com, 2026-09-24)
TickrTrends take: Insulet Corporation's participation in high-profile healthcare industry forums highlights the company's positioning among sector leaders, which aligns with TickrTrends' assessment of PODD as undervalued within the Healthcare sector. For valuation-focused investors, such visibility at industry events may signal management confidence and could influence how the market perceives the company's competitive standing relative to its current pricing. Monitoring the outcomes and insights from such forums may provide context for whether the market's valuation of PODD reflects the company's actual competitive positioning and growth prospects. - Insulet Corporation (PODD) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript (seekingalpha.com, 2026-09-24)
TickrTrends take: Insulet's participation in high-profile healthcare forums underscores its positioning as an innovation leader in the sector, which TickrTrends currently identifies as undervalued. For valuation-focused investors, monitoring management commentary at such events can reveal insights into the company's growth strategy and competitive differentiation that may inform whether current pricing reflects its full potential in the healthcare market. The forum appearance represents an opportunity for the market to reassess Insulet's trajectory against its current valuation metrics. - Insulet (PODD) Refinances $475 Million Term Loans and Expands Revolving Credit Facility to $750 Million (gurufocus.com, 2026-09-22)
TickrTrends take: Insulet's refinancing of 475 million dollars in term loans and expansion of its revolving credit facility to 750 million dollars demonstrates the company's ability to access capital markets and strengthen its financial position. TickrTrends currently rates PODD as undervalued within the Healthcare sector, suggesting that improved liquidity and financial flexibility from this refinancing may not yet be fully reflected in the stock's current valuation. Investors focused on valuation metrics should monitor whether this enhanced financial capacity translates into operational improvements or strategic investments that could support future growth narratives.
What people are saying
Follow the PODD conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is PODD stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), PODD is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is PODD's TickrTrends verdict?
PODD's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does PODD compare to other Healthcare stocks?
PODD ranks #96 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is PODD overbought or oversold?
PODD's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does PODD report earnings next?
PODD's next earnings report is scheduled for 2026-11-04 (pre-market), per the published earnings calendar.
Does PODD usually beat earnings estimates?
Over its last 8 reported quarters PODD beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about PODD?
Of 25 analysts covering PODD, 15 rate it a buy, 10 a hold and 0 a sell - buy-leaning, with a consensus price target of $167 (+23.4% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
PODD vs ADMA · PODD vs ALGN · PODD vs ANIP · PODD vs ASTH · PODD vs AZN